Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma. % Reactive Fragments 65.2 ± 26.8 43.0 ± 46.2 % CD56 + of TIL Expansion 14.1 ± 26.2 9.8 ± 4.6 % CD3 + of TIL ...

Currently, tumor-infiltrating B lymphocytes have been recognized as a new hallmark of breast cancer (BC). The function seems to be controversial, either with positive, negative, or no significance in ...

Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the ...

Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...

In its 10-K report, Iovance Biotherapeutics highlighted its commercialization efforts for Amtagvi, the first product within ...

Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M ...

Although it reported 2024 Q4 and full-year results that beat expectations and reiterated 2025 guidance that includes ...